HOME >> BIOLOGY >> NEWS
Memorial Sloan-Kettering Investigators

hat determines which patients respond to RA and which ones don't have identified a genetic difference between the two groups. APL patients who do well on RA treatment have leukemia that results from the fusion of two genes called PML and RAR-alpha (PML-RAR ), while the leukemia of patients who are resistant to RA is caused by a fusion of the genes PLZF and RAR-alpha (PLZF-RAR ).

To study these minute genetic differences further, Dr. Pandolfi and his colleagues developed two groups of mice: One group harbored the PML-RAR gene fusion, while a second group had the PLZF-RAR gene fusion. Both groups of mice developed APL similar to that seen in humans. In normal cells, certain proteins called transcription factors -- such as RAR -- turn on the expression of other genes with specific functions, such as controlling cell growth and maturation. Using advanced analytical techniques, Dr. Pandolfi's group showed that unlike RAR , proteins produced by the PML-RAR and PLZF-RAR gene fusions turned off, or "repressed," the expression of the cell's genes that normally prompt a cell to mature into a healthy, functioning white blood cell. Because these genes were turned off, the cells didn't mature, and leukemia developed. Moreover, the investigators found that PML-RAR and PLZF-RAR were acting as transcription repressors because of their ability to interact with other proteins. In PML- RAR , these interactions were broken apart by RA, while in PLZF-RAR they were insensitive to RA, explaining why retinoic acid works in some APL patients but not others.

Armed with this new knowledge, the MSKCC researchers set out to find ways to undo this chain of events. They knew that genetic material in a chromosome is tightly held together by proteins called histones. However, histones prevent individual gene expression. Previous studies of histones have shown that transcription repressors may work by favoring the place
'"/>

Contact: Kelli Stauning
stauningk@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
26-Jan-1998


Page: 1 2 3 4

Related biology news :

1. Veterinary Memorial Fund transforms grief into promise
2. Andres Vazquez-Torres honored with 2004 Merck Irving S. Sigal Memorial Award
3. American Society for Microbiology honors Timothy Yahr with 2004 Merck Irving S. Sigal Memorial Award
4. Childrens Memorial, TGen announce partnership
5. Webcast of NSF Director Rita Colwells Chafee Memorial Lecture
6. Director of Emory Vaccine Center to give Wistar Institutes 1999 Tadeusz J. Wiktor Memorial lecture
7. Snapshot of new drug marks a major advance by Memorial Sloan-Kettering researchers
8. Chern Memorial Award Presented To Wistar Institute Postdoctoral Fellow
9. APS announces four 2004 Young Investigators awards
10. EMBO Young Investigators 2000 2002
11. Investigators use guilt-by-association strategy to track potential cancer causing genes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):
(Date:6/22/2017)... ... June 22, 2017 , ... The first human cell ... years until the first data on cross-contamination of human cell lines with HeLa cells ... increasing issue in cell culture labs and is associated with dramatic consequences for research. ...
(Date:6/20/2017)... ... June 20, 2017 , ... CTNext , ... directors has formed a Higher Education Entrepreneurship Advisory Committee to implement the recommendations ... and other high-ranking representatives from 35 higher education institutions across the state over ...
(Date:6/20/2017)... , June 20, 2017  Kibow Biotech Inc., a ... announce the issuance of a new patent covering a ... by the U.S. Patent and Trademark Office on May ... of the Buzz of Bio award in 2014 in ... to developing non-drug approaches to chronic disease. Renadyl™, the ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... antibody therapeutics from millions-diverse immune repertoires, announces launch of its new Surge(TM) ... Dave Johnson, PhD, CEO of GigaGen, will present on Surge at the conference. ...
Breaking Biology Technology:
Cached News: